Martin Dreyling
机构: Professor of Medicine, University of Munich
每年引用次数
引用次数
引用: 50,014
H-指数: 101
I10-指数 : 406
出版物: 1,095
Phase IIa study of copanlisib, a novel phosphatidylinositol-3 kinase inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma
Catherine Thieblemont , Umberto Vitolo , Franck Morschhauser , Kim Linton
In: EORTC-NCI-AACR meeting; Barcelona, Spain. 2014.
2014
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
Stephan Bayerl , Wolfgang Hiddemann , Anna-Katharina Zoellner , Martin Dreyling
Leukemia & Lymphoma 56 ( 12) 3393 -3400
8
2015
Current status and perspective of antibody therapy in follicular lymphoma
Oliver Weigert , Michael Unterhalt , Wolfgang Hiddemann , Martin Dreyling
Haematologica 91 ( 1) 104 -112
23
2006
Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer.
Walter M. Stadler , Olufunmilayo I. Olopade , Martin Dreyling , Stefan K. Bohlander
Cancer Research 54 ( 8) 2060 -2063
79
1994
Precision medicine in diffuse large B-cell lymphoma: hitting the target.
Marie José Kersten , Steven T. Pals , Anas Younes , Massimo Federico
Haematologica 100 ( 8) 989 -993
13
2015
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent events
Torsten Haferlach , Wolfgang Hiddemann , Martin Dreyling , Yvonne Zimmermann
Haematologica 90 ( 5) 693 -695
12
2005
NEWS & VIEWS 血液がん : MCLへのボルテゾミブ投与 : 新規標準治療か、それとも単なる1つの選択肢か?
Martin Dreyling
Cancer and clinical oncology 5 ( 4) 177 -179
2015
Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, idolent or aggressive lymphoma
Kim Linton , Marius Giurescu , Julia Grunert , David Cunningham
British Society for Haematology 55th Annual Scientific Meeting
2015
Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis
Tait D. Shanafelt , Michael S. Ewer , Javid Moslehi , Steven E. Coutre
Blood 130 1743 -1743
1
2017
The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)
Monika Szczepanowski , Oliver Weigert , Oliver Weigert , Randy D. Gascoyne
Blood 130 2735 -2735
2017
Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis
Fong Clow , Jose Angel Hernandez-Rivas , Brad S Kahl , Anil Londhe
Blood 130 151 -151
7
2017
Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities
Massimo Magagnoli , Franck Morschhauser , Pier Luigi Zinzani , Judit Demeter
Blood 130 2777 -2777
3
2017
Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial
Stephan Stilgenbauer , Marek Trneny , Catherine Thieblemont , Eva Hoster
Blood 130 153 -153
18
2017
Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib
Franck Morschhauser , Pier Luigi Zinzani , Gilles Andre Salles , David Cunningham
Blood 130 4042 -4042
3
2017
Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial
Pier Luigi Zinzani , Arnon Nagler , George Follows , Panayiotis Panayiotidis
Blood 130 4053 -4053
2
2017
MCP (Mitoxantrone/Chlorambucil/Prednisolone) Chemotherapy Impairs the Subsequent Collection of Stem Cells in Comparison to CHOP Induction in Patients with Indolent Lymphomas - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
Hannes Wandt , Christina Nickenig , Eva Hoster , Michael Unterhalt
Blood 106 ( 11) 3331 -3331
1
2005
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.
Daniela Drandi , Marion Alcantara , Ichrafe Benmaad , Arian Söhlbrandt
HemaSphere 4 ( 2)
11
2020
A closer look at copanlisib.
Martin Dreyling
Clinical advances in hematology & oncology 16 ( 1) 35 -37
1
2018
Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma
Steven Le Gouill , Herve Maisonneuve , Roch Houot , Marita Ziepert
Blood 136 32 -32
2020
Double Hit Lymphoma Diagnosis and Treatment in Europe-A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG).
Martine E. D. Chamuleau , Marie Jose Kersten , Kim Linton , Massimo Federico
Hemasphere 4 ( 6)
2020